Archive

Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

A new GLP-1 for obesity and diabetes is entering Europe; watch for pricing and supply competition that may affect your patients' access.

Endocrinology · Fierce Biotech · 4 Sept

Medulance Raises ₹24 Cr To Expand Emergency Response Network

Expands ambulance availability and response times for your patients in emergencies, potentially improving critical care access across cities.

General Medicine · Inc42 · 4 Sept

Smoking raises death risk by 55% in people with diabetes, global experts call for active quit treatment

For your diabetic patients who smoke, actively offer cessation—this consensus quantifies a 55% higher death risk and urges routine intervention.

Endocrinology · ETHealthworld · 4 Sept

FSSAI plans curbs on high-fat food sales within 50 metres of schools, CEO Rajit Punhani says

This may reduce childhood obesity and metabolic risk; paediatricians should counsel families on healthier snack choices near schools.

Paediatrics · ETHealthworld · 4 Sept

FDA Approves First Drug to Treat Alexander Disease

First-ever therapy for a fatal leukodystrophy; consider referral for pediatric or adult patients with confirmed GFAP mutation.

Neurology · FDA — Press Announcements · 4 Sept

Ultrahuman Bags $70 Mn To Build An Integrated Healthtech Platform

This funding expands wearable health monitoring, potentially aiding early detection of metabolic and cardiac issues in your patients.

Medicine · Inc42 · 3 Sept

GenHealth.ai secures $16.5M in series A for back-office AI agents

If adopted, these agents could reduce manual revenue-cycle work across EHRs and payer portals, freeing staff time and potentially improving claim throughput.

Medicine · Fierce Healthcare · 3 Sept

STAT+: OpenEvidence launches new family of AI models

If these models improve clinical evidence retrieval, you may get faster, more accurate answers at the point of care—worth trialing in your workflow.

General Medicine · STAT News — Health Tech · 3 Sept

Psilocybin proves promising in neuropathic pain mouse study

If confirmed in humans, psilocybin could offer a new option for chemotherapy-induced neuropathy, which often resists standard painkillers.

Neurology · Fierce Biotech · 3 Sept

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

For relapsed/refractory myeloma patients who have exhausted standard options, etentamig offers a new bispecific with improved PFS—consider as a later-line therapy.

Oncology · Fierce Biotech · 3 Sept

STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized

FDA's TEMPO pilot may let AI tools like Cadence and Limbic reach your patients pre-authorization—know their evidence limits before you rely on them.

Medicine · STAT News — Health Tech · 3 Sept

OpenEvidence deepens oncology push to enhance specialized AI agent, launches new AI model family

Specialised AI agents may give faster, more accurate oncology answers at the point of care, potentially aiding treatment decisions.

Oncology · Fierce Healthcare · 3 Sept

Scientists find genes linked to OCD, raising the prospect of new treatments

Identifies specific genetic loci for OCD, guiding future targeted therapies and better risk stratification for your patients with refractory symptoms.

Psychiatry · ETHealthworld · 3 Sept

Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.

Xenograft sustained dialysis independence for 271 days. Early T-cell rejection resolved. Later graft failure from thrombotic microangiopathy despite negative crossmatch. No porcine pathogen transmission. Anti-HLA antibodies unchanged. Human transplant succeeded with 231 days follow-up.

General Surgery · Lancet · 3 Sept

Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.

Cumulative incidence of epilepsy increased from 9.5% (95% CI 7.8-11.3) at Alzheimer's diagnosis to 56.9% (51.7-61.7) after 9 years. Epilepsy associated with increased mortality (HR 2.10 [95% CI 1.57-2.82]; p<0.0001) and faster cognitive decline.

Neurology · Lancet · 3 Sept

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

This deal may bring a novel KRAS-EGFR targeted therapy to your patients with solid tumors, potentially expanding options beyond current KRAS inhibitors.

Oncology · Fierce Biotech · 3 Sept

Pulmonary Nodules.

Solid nodules stable for 2 years considered benign; subsolid nodules require longer stability. Subsolid nodules slower growing but higher malignancy risk, especially if solid component develops.

Radiology · NEJM · 3 Sept

Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.

Argues first-generation viruses and checkpoint inhibitors rely on pre-existing tumour-specific T cells. Next-generation viruses act as antigen-agnostic in situ vaccines, with early data showing T-cell broadening, abscopal responses, and survival benefit in ICI-refractory disease.

Medicine · Nature reviews. Clinical oncology · 3 Sept

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Median event-free survival 14.5 months (95% CI 10.4-24.4) with azacitidine-venetoclax vs 6.2 months (95% CI 4.1-10.1) with induction; HR 0.57 (95% CI 0.39-0.84, P=0.002).

Oncology · NEJM · 3 Sept

Genetic evidence supports the combined targeting of lipoprotein(a) and LDL cholesterol to reduce coronary artery disease risk.

LPA or PCSK9 loss-of-function carriers had lower CAD risk than noncarriers (odds ratio 0.91 and 0.81); carriers of both had lower risk still (OR 0.73). Genetic lowering of Lp(a) and LDL-C gave OR 0.70 versus OR 0.85 and 0.81 individually.

Medicine · Nature cardiovascular research · 3 Sept

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Objective response: 31% at ≤120 mg, 34% at 160-220 mg, 37% at 300 mg. Grade 3+ adverse events in 54%; pneumonia 10%, diarrhea 9%, rash 8%, anemia 5%; four grade 5 events.

Oncology · NEJM · 3 Sept

BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.

A rapid and sustained reduction of the intact SIV reservoir was seen in venetoclax-treated rhesus macaques in blood and lymph nodes.

Medicine · Nature microbiology · 3 Sept

ANA: Individuals, employers share responsibility in tackling nurse fatigue

For clinicians, this shifts fatigue from personal failing to systemic duty—prompting safer staffing and rest policies that protect you and your patients.

Medicine · Fierce Healthcare · 2 Sept

Vitamin D3 more effective than Vitamin D2 in maintaining muscle, heart health: ICMR-NIN study

Prefer D3 supplements for patients needing vitamin D, as D2 may inadequately protect muscle and cardiac structure.

Endocrinology · ETHealthworld · 2 Sept

Leading medical groups release flu, COVID vaccine recommendations as CDC guidance lags

With CDC silent, these recommendations give you a clear vaccination schedule for flu and COVID to follow this season.

General Medicine · Fierce Healthcare · 2 Sept

Teva autoimmune antibody notches ph. 2 win in celiac disease

For celiac patients who still flare on a gluten-free diet, this IL-15 blocker may offer the first targeted option—watch for phase 3.

Gastroenterology · Fierce Biotech · 2 Sept

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

Vaccine effectiveness against hospitalization: 53.0% (95% CI, 37.0%-65.0%) in ≥65 years (2025-26) and 54.0% (95% CI, 1.0%-78.0%) in 18-64 years (2024-25). Maternal vaccination reduced infant hospital contacts by 50.0%-54.0%.

General Medicine · JAMA · 2 Sept

Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?

A phase 3 mRNA vaccine plus pembrolizumab improved survival in resected high-risk melanoma; expect referral pathways and adjuvant trial discussions to shift if approved.

Oncology · Fierce Biotech · 1 Sept

ChatGPT for Healthcare unveils new integrations with Epic, public health data sources

If you use Epic, ChatGPT may soon sit inside your workflow, pulling patient data and public health context—potentially saving clicks but demanding vigilance on accuracy.

General Medicine · Fierce Healthcare · 1 Sept

Cureety acquires Reimagine Care for AI-driven precision oncology

This merger expands AI-driven remote monitoring and care pathways to over 250 cancer centers, potentially improving symptom management and outcomes for your patients.

Oncology · Fierce Healthcare · 1 Sept

Surge in H1N1 cases isn’t unusual, vigilance remains key: Doctors

Reassures you that current H1N1 rise is seasonal, not a new strain—so continue standard testing and antiviral protocols without alarm.

General Medicine · ETHealthworld · 1 Sept

UnitedHealthcare to nix prior auth on 1,700 services on Oct. 1

Fewer prior auths mean faster approvals for your patients' common procedures, but verify which services qualify before assuming coverage changes.

General Medicine · Fierce Healthcare · 1 Sept

Nourish embeds generative AI assistant into patient app for 24/7 support

Gives your patients between-visit meal planning, lab insights, and prep support—could reduce phone calls and improve adherence, but evidence is thin.

General Medicine · Fierce Healthcare · 1 Sept

Drug-resistant infections kill more, cost more: ICMR study

For clinicians, this quantifies the mortality and cost burden of resistant Gram-negative infections, urging early culture-guided therapy and stewardship.

General Medicine · ETHealthworld · 1 Sept

GSK catches phase 3 fever after mRNA flu vaccine beats standard shots

If phase 3 confirms, mRNA flu shots could offer better protection than current vaccines, changing your seasonal flu recommendations.

General Medicine · Fierce Biotech · 1 Sept

Regulation of General Wellness Devices

Clarifies which consumer wellness products need FDA oversight, helping you advise patients on safe digital health tools.

Medicine · JAMA · 1 Sept

Recommendations for Nicotine E-Cigarettes for Smoking Cessation

Helps you counsel adult smokers on e-cigarette use, balancing potential benefits against unknown long-term risks.

General Medicine · JAMA · 1 Sept

Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer

High-dose vitamin D3 may extend progression-free survival in untreated metastatic colorectal cancer—consider adding it to standard chemotherapy.

Oncology · JAMA · 1 Sept

First Once-Weekly Oral HIV Treatment Demonstrates Safety and Efficacy

Weekly oral regimen could replace daily pills, easing adherence burden for stable HIV patients on suppressive therapy.

General Medicine · JAMA · 1 Sept